System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Practice Guideline Ppublish

PubMed: 40409689 DOI: 10.1016/j.jtct.2025.05.001

American Society for Transplantation and Cellular Therapy Series #9: Management of Human Herpesvirus 6B After Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T-Cell Therapy.

Transplant Cell Ther 31(8):480-493

Authors: Eleftheria Kampouri, Guy Handley, Tuan L Phan, Yeon Joo Lee, Ryan Shaw, Paul A Carpenter, Sanjeet S Dadwal, Roy F Chemaly, Genovefa A Papanicolaou, Masao Ogata, Michael Boeckh, Danielle M Zerr, Joshua A Hill

Affiliations

  • Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
  • Department of Medicine, Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medicine, New York, New York.
  • Department of Pharmacy, University of North Carolina, Chapel Hill, North Carolina.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Pediatrics, University of Washington, Seattle, Washington.
  • Department of Medicine, Division of Infectious Disease, City of Hope National Medical Center, Duarte, California.
  • Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
  • Department of Pediatrics, University of Washington, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.

Abstract

The Practice Guidelines Committee and the Transplant Infectious Disease Special Interest Group of the American Society for Transplantation and Cellular Therapy developed guidelines focusing on human herpesvirus 6B (HHV-6B). A compendium-style approach was used to address a series of standalone frequently asked questions (FAQs), supported by tables and figures to spotlight key concepts. Adult and pediatric infectious disease and hematopoietic cell transplantation (HCT) content experts developed these FAQs and finalized recommendations after consensus was reached. This ninth topic in the series focuses on the relevant risk factors, diagnostic considerations, prophylaxis, and treatment approaches relevant to HHV-6B infections after HCT and chimeric antigen receptor-T-cell therapy.

MeSH

Cells, Hematopoietic Stem Cell Transplantation, Receptors, Antigen, Receptors, Chimeric Antigen, Therapeutics, Cell Transplantation, T-Lymphocytes, Encephalitis, Transplantation, Car-T Cell